| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Sugimot. Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chemical record (New York, N.Y.). vol 1. issue 1. 2003-04-22. PMID:11893059. |
the role of the cholinergic system with respect to cognitive deficits characteristic of alzheimer's disease (ad) has led to a number of studies focusing on the development of acetylcholinesterase (ache) inhibitors as a drug for treating this disease. |
2003-04-22 |
2023-08-12 |
Not clear |
| Joana Barbosa Melo, Paula Agostinho, Catarina Resende Oliveir. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neuroscience research. vol 45. issue 1. 2003-04-08. PMID:12507730. |
acetylcholinesterase (ache) activity is increased within and around amyloid plaques, which are present in alzheimer's disease (ad) patient's brain. |
2003-04-08 |
2023-08-12 |
Not clear |
| Valtteri Kaasinen, Kjell Någren, Tarja Järvenpää, Anne Roivainen, Meixiang Yu, Vesa Oikonen, Timo Kurki, Juha O Rinn. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Journal of clinical psychopharmacology. vol 22. issue 6. 2003-03-31. PMID:12454562. |
donepezil and rivastigmine are acetylcholinesterase (ache) inhibitors used to improve cholinergic neurotransmission and cognitive function in alzheimer's disease (ad). |
2003-03-31 |
2023-08-12 |
human |
| L Parnetti, S Amici, A Lanari, C Romani, C Antognelli, N Andreasen, L Minthon, P Davidsson, H Pottel, K Blennow, V Galla. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 23 Suppl 2. 2003-03-28. PMID:12548360. |
in order to evaluate the biochemical effects of long-term treatment with inhibitors of acetylcholinesterase (ache) in patients with alzheimer's disease (ad), we measured the activities of ache and butyrylcholinesterase (buche) and the concentrations of beta-amyloid (1-42), tau and phosphorylated tau proteins in the cerebrospinal fluid (csf). |
2003-03-28 |
2023-08-12 |
Not clear |
| Dawn M Wong, Harry M Greenblatt, Hay Dvir, Paul R Carlier, Yi-Fan Han, Yuan-Ping Pang, Israel Silman, Joel L Sussma. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. Journal of the American Chemical Society. vol 125. issue 2. 2003-03-14. PMID:12517147. |
acetylcholinesterase (ache) inhibitors improve the cognitive abilities of alzheimer patients. |
2003-03-14 |
2023-08-12 |
mouse |
| Hiroki Namba, Kiyoshi Fukushi, Shin-ichiro Nagatsuka, Masaomi Iyo, Hitoshi Shinotoh, Shuji Tanada, Toshiaki Iri. Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates. Methods (San Diego, Calif.). vol 27. issue 3. 2003-03-04. PMID:12183113. |
studies on patients with alzheimer's disease demonstrated a widespread reduction of ache activity in the cerebral cortex (more profound in early-onset than in late-onset alzheimer's disease). |
2003-03-04 |
2023-08-12 |
human |
| Manuela Bartolini, Carlo Bertucci, Vanni Cavrini, Vincenza Andrisan. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochemical pharmacology. vol 65. issue 3. 2003-02-13. PMID:12527333. |
incubation experiments were performed in the presence of known ache inhibitors (physostigmine, edrophonium, decamethonium, propidium) and drugs used for alzheimer's disease (ad) (tacrine, donepezil), to test their capability of preventing the huache-induced abeta aggregation. |
2003-02-13 |
2023-08-12 |
human |
| X J Zhang, L Yang, Q Zhao, J P Caen, H Y He, Q H Jin, L H Guo, M Alemany, L Y Zhang, Y F Sh. Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell death and differentiation. vol 9. issue 8. 2003-01-31. PMID:12107822. |
it has been suggested that ache may participate in development, differentiation, and pathogenic processes such as alzheimer's disease and tumorigenesis. |
2003-01-31 |
2023-08-12 |
Not clear |
| S Auriacombe, J J Pere, Y Loria-Kanza, B Vella. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Current medical research and opinion. vol 18. issue 3. 2003-01-22. PMID:12094822. |
selective acetylcholinesterase (ache) and dual acetyl- and butyrylcholinesterase inhibitors constitute the only approved agents for the symptomatic treatment of alzheimer's disease (ad). |
2003-01-22 |
2023-08-12 |
Not clear |
| Jenny Apelt, Ashok Kumar, Reinhard Schlieb. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain research. vol 953. issue 1-2. 2003-01-10. PMID:12384234. |
to address the question of whether beta-amyloid peptides also affect cholinergic neurotransmission in vivo, brain tissue from transgenic tg2576 mice with alzheimer plaque pathology at ages ranging from 7 to 24 months were examined by immuno- and histochemical staining for choline acetyltransferase (chat) and acetycholinesterase (ache), by assaying cholinergic enzyme activities and high-affinity choline uptake as well muscarinic and nicotinic cholinergic receptor binding levels by quantitative autoradiography. |
2003-01-10 |
2023-08-12 |
mouse |
| C Flores-Flores, A Nissim, S Shochat, H Sore. Development of human antibody fragments directed towards synaptic acetylcholinesterase using a semi-synthetic phage display library. Journal of neural transmission. Supplementum. issue 62. 2003-01-10. PMID:12456061. |
current alzheimer's disease therapies suppress acetylcholine hydrolysis by inhibiting acetylcholinesterase (ache) at cholinergic synapses. |
2003-01-10 |
2023-08-12 |
human |
| Jeffrey Sterling, Yaacov Herzig, Tamar Goren, Nina Finkelstein, David Lerner, Willy Goldenberg, Istvan Miskolczi, Sandor Molnar, Ferenc Rantal, Tivadar Tamas, Gyorgy Toth, Adela Zagyva, Andras Zekany, John Finberg, Gila Lavian, Aviva Gross, Rachel Friedman, Michal Razin, Wei Huang, Boris Krais, Michael Chorev, Moussa B Youdim, Marta Weinstoc. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. Journal of medicinal chemistry. vol 45. issue 24. 2002-12-20. PMID:12431053. |
novel dual inhibitors of ache and mao derived from hydroxy aminoindan and phenethylamine as potential treatment for alzheimer's disease. |
2002-12-20 |
2023-08-12 |
Not clear |
| Jeffrey Sterling, Yaacov Herzig, Tamar Goren, Nina Finkelstein, David Lerner, Willy Goldenberg, Istvan Miskolczi, Sandor Molnar, Ferenc Rantal, Tivadar Tamas, Gyorgy Toth, Adela Zagyva, Andras Zekany, John Finberg, Gila Lavian, Aviva Gross, Rachel Friedman, Michal Razin, Wei Huang, Boris Krais, Michael Chorev, Moussa B Youdim, Marta Weinstoc. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. Journal of medicinal chemistry. vol 45. issue 24. 2002-12-20. PMID:12431053. |
compounds with such dual ache and mao inhibitory activities are expected to have potential for the treatment of alzheimer's disease. |
2002-12-20 |
2023-08-12 |
Not clear |
| Matthew G Cottingham, Michael S Hollinshead, David J T Vau. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry. vol 41. issue 46. 2002-12-19. PMID:12427014. |
a region near the c-terminus of human acetylcholinesterase (ache) is weakly homologous with the n-terminus of the alzheimer's disease amyloid-beta peptide. |
2002-12-19 |
2023-08-12 |
human |
| Matthew G Cottingham, Michael S Hollinshead, David J T Vau. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry. vol 41. issue 46. 2002-12-19. PMID:12427014. |
ache normally resides mainly on cholinergic neuronal membranes, but is abnormally localized to senile plaques in alzheimer's disease. |
2002-12-19 |
2023-08-12 |
human |
| A Desai, G Grossber. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Expert opinion on pharmacotherapy. vol 2. issue 4. 2002-11-06. PMID:11336614. |
rivastigmine (exelontrade mark, novartis) is a novel intermediate-acting reversible and non-competitive carbamate acetylcholinesterase (ache) that was recently introduced for the treatment of alzheimer's disease (ad). |
2002-11-06 |
2023-08-12 |
Not clear |
| Ho-Jin Heo, Seong-Chan Hong, Hong-Yon Cho, Bumshik Hong, Hye-Kyung Kim, Eun-Ki Kim, Dong-Hoon Shi. Inhibitory effect of zeatin, isolated from Fiatoua villosa, on acetylcholinesterase activity from PC12 cells. Molecules and cells. vol 13. issue 1. 2002-10-10. PMID:11911460. |
acetylcholinesterase (ache) inhibitors, which enhance cholinergic transmission by reducing the enzymatic degradation of acetylcholine, are the only source of the compound that is currently approved for the treatment of alzheimer's disease (ad). |
2002-10-10 |
2023-08-12 |
Not clear |
| T Carbonell, I Masip, F Sánchez-Baeza, M Delgado, E Araya, O Llorens, F Corcho, J J Pérez, E Pérez-Payá, A Messegue. Identification of selective inhibitors of acetylcholinesterase from a combinatorial library of 2,5-piperazinediones. Molecular diversity. vol 5. issue 3. 2002-09-30. PMID:12197070. |
overall the present results indicate that the dkp-based compounds identified are novel ache inhibitors which may be considered likely lead compounds for further development of drug candidates against alzheimer's disease. |
2002-09-30 |
2023-08-12 |
Not clear |
| P Tario. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Expert opinion on pharmacotherapy. vol 2. issue 12. 2002-09-26. PMID:11825333. |
galantamine is a newly available cholinergic drug that offsets reductions in central cholinergic neurotransmission in alzheimer's disease (ad) by specifically and reversibly inhibiting acetylcholinesterase (ache) and by allosterically modulating nicotinic cholinergic receptors. |
2002-09-26 |
2023-08-12 |
Not clear |
| J Poirie. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. International journal of clinical practice. Supplement. issue 127. 2002-09-12. PMID:12139368. |
tacrine and rivastigmine inhibit both acetylcholinesterase (ache) and butyrylcholinesterase (buche) in the csf of alzheimer's disease patients. |
2002-09-12 |
2023-08-12 |
human |